17 January 2012 - Xenetic Biosciences Plc (LON:XEN), the UK-based company specialising in engaged in the development of drug and vaccine delivery systems, said on Tuesday that it had completed the acquisition of India's SymbioTec Pharmalab Ltd.

Xenetic has allotted 80m acquisition shares to the sellers and has filed an application for admission to London Stock Exchange's Alternative Investment Market (AIM). The acquisition shares are expected to be admitted to trading on 20 January 2012.

Moreover, Xenetic has concluded all of its proposed arrangements with the Serum Institute of India (SIIL), including the legal completion of the new master agreement. Xenetic has allotted 9m new ordinary shares and SIIL has also subscribed for a further 2.5m new ordinary shares at a price of GBP0.11 (USD0.17/EUR0.13) per share, thus raising GBP275,000 of new capital for Xenetic.

(GBP1 = USD1.537/EUR1.207)